Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk liver tissue RNA-seq was performed using the vector control livers and that with c-Met/ΔN90-β-catenin SB-HTVI for 2 and 3 weeks

ABSTRACT: Bulk RNA-seq of the liver tissues at early time points after c-Met/β-catenin expression (2 and 3 weeks) showed changes of gene expression of cell growth/migration, carbohydrate metabolism, and lipid metabolism.

ORGANISM(S): Mus musculus

PROVIDER: GSE310076 | GEO | 2025/12/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Bulk RNA-seq of the CD and LPD-fed mice injected with vector control or c-Met/ΔN90-β-catenin by SB-HTVI

Project description:We performed bulk RNA-seq to compare liver tissues from 4 groups of mice: vector control fed with CD, c-Met/β-cat mice fed with CD, vector control fed with LPD, and c- Met/β-cat mice fed with LPD. Differential gene expression and gene set enrichment analyses (GSEA) were performed and identified two clusters that might help explain the differential tumor development in the CD and LPD groups.

2025-12-08 | GSE310077 | GEO

Gene expression profiling of mouse liver cells treated with or without MET/CAT and SB transposase

Project description:mice were induced with MET/CAT and SB for 0, 2 or 7 weeks , then mRNA were extracted for high-throughput sequencing

2020-07-29 | GSE155284 | GEO

Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin–mediated prostatic tumorigenesis

Project description:Co-occurrence of aberrant hepatocyte growth factor (HGF)/MET proto-oncogene receptor tyrosine kinase (MET) and Wnt/β-catenin signaling pathways has been observed in advanced and metastatic prostate cancers. This co-occurrence positively correlates with prostate cancer progression and castration-resistant prostate cancer (CRPC) development. However, the biological consequences of these abnormalities in these disease processes remain largely unknown. Here, we investigated the aberrant activation of HGF/MET and Wnt/β-catenin cascades in prostate tumorigenesis by using a newly generated mouse model in which both murine Met transgene and stabilized β-catenin are conditionally co-expressed in prostatic epithelial cells. These compound mice displayed accelerated prostate tumor formation and invasion compared with their littermates that expressed only stabilized β-catenin.RNA-Seq and qRT-PCR analyses revealed increased expression of genes associated with tumor cell proliferation, progression,and metastasis. Moreover, Wnt signaling pathways were robustly enriched in prostate tumor samples from the compound mice.ChIP-qPCR experiments revealed increased β-catenin recruitment within the regulatory regions of the Myc gene in tumor cellsof the compound mice. Interestingly, the occupancy of MET on the Myc promoter also appeared in the compound mouse tumor samples,implicating a novel role of MET in β-catenin–mediated transcription. Results from implanting prostate graft tissues derived from the compound mice and controls into HGF-transgenic mice further uncovered that HGF induces prostatic oncogenic transformation and cell growth. These results indicate a role of HGF/MET in β-catenin–mediated prostate cancer cell growth and progressionand implicate a molecular mechanism whereby nuclear MET promotes aberrant Wnt/β-catenin signaling–mediated prostate tumorigenesis.

2019-12-17 | GSE142158 | GEO

MET Inhibition Elicits PGC1α Dependent Metabolic Reprogramming in Glioblastoma

Project description:By utilizing proteomic and transcriptomic analysis coupled with untargeted polar and non-polar metabolite analysis by liquid chromatography/mass spectrometry, we identified a specific metabolic program elicited by c-MET inhibition. Interference with c-MET drives oxidative metabolism by increasing fatty acid oxidation (FAO) and glucose anaplerosis, which was orchestrated by the master-regulator, PGC1α. Based on a drug screen, we further found that the mitochondrial matrix chaperone inhibitor, gamitrinib, along with c-MET inhibition causes synergistic cell death, which was mechanistically related to the ability of gamitrinib to suppress oxidative metabolism. In alignment with these findings, FAO inhibitor, etomoxir, enhanced the anti-proliferative effects of c-MET inhibition as well. Both combination therapies were active in vivo, suggesting two novel potential combination therapies, involving c-MET inhibitors.

2020-07-22 | GSE134676 | GEO

Single-nucleus RNA-seq reveals reprogrammed hepatocytes that express c-Met/β-catenin oncogenes in LPD-fed mice.

Project description:To further interrogate the impact of low protein diet (LPD) on the c-Met/β-catenin expressing hepatocytes, we performed single-nucleus RNA-sequencing (snRNA-seq) analysis. Mice were fed on chow diet (CD) or LPD for one week, followed by SB-HTVI of c-Met/β-catenin. Two weeks post SBHTVI, 42,277 single nuclei were sequenced with 12,413 in the CD-vector control, 10,225 in CD c-Met/β-cat, 9,707 in LPD-vector control, and 9,932 in LPD c-Met/β-cat.

2025-12-08 | GSE311624 | GEO

β-catenin deficiency in hepatocytes promotes liver tumorigenesis driven by oncogenic β-Catenin and c-Met in mice

Project description:To understand differential gene expression globally with/without hepatocyte β-catenin knockout on liver cancer mouse model, RNA-seq analysis were examined using hydrodynamic β-catenin and c-Met induced β-catenin∆H (β-cateninF/F:Alb-cre) and WT mice.

2017-04-25 | GSE97914 | GEO

Transcriptome analysis of MET-constitutively active versus MET-silenced colorectal cancer cells

Project description:To investigate the expression patterns driven by hyperactivated MET in MET-dependent cells, we employed LoVo colon adenocarcinoma cell line, harbouring a post-translational modification of MET that leads to its constitutive activation. We then silenced MET in LoVo cells using CRISPR/Cas9 knock-out (KO) protocol, and performed gene expression profiling analysis using data obtained from RNA-seq of cells with hyperactivated-MET versus MET-KO.

2023-10-14 | GSE212835 | GEO

MET/ETS

Project description:MET and ETS collaboration in prostate cancer

| PRJEB67887 | ENA

Expression data of Met-low and Met-high B16-F10 malignant melanoma cells

Project description:B16-F10 malignant mouse melanoma cells have been frequently used as highly metastatic cells. Based on heterogenous cell surface expression of Met/HGF (hepatocyte growth factor) receptor in B16-F10 cells, the cells were divided into Met-low and Met-high cells by flow cytometry and these populations were subjected to microarray analysis. Met-low and Met-high cells showed different expression profiles in genes involved characteristics of tumors, including stem cell maintenance, pigmentation, and angiogenesis.

2016-09-25 | GSE69741 | GEO

RNA sequence for mammary gland of ICR mice at pregnant day 17 with supplementation of methionine (Met) alone or with methionyl-methionine (Met-Met) dipeptide.

Project description:Using RNA-seq to explore the mechanisms underlysing the effects of methionyl-methionine dipeptide (Met-Met) or free methionine (Met) supplementation in Met-restricted mice during pregnancy on mammogenesis and lactation.

2022-04-02 | GSE129224 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data